Mycophenolate mofetil in the treatment of lupus nephritis

Patrick FK Yong1,2, David P D&rsquo;Cruz21Department of Clinical Immunology, Kings College Hospital; 2The Lupus Research Unit, St Thomas&rsquo; Hospital, London, UKAbstract: Lupus nephritis is a complication of systemic lupus erythematosus, which has significant morbidity and mortali...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Patrick FK Yong, David P D&rsquo;Cruz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4c286db1b05d497ea6a619416308f8e8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4c286db1b05d497ea6a619416308f8e8
record_format	dspace
spelling	oai:doaj.org-article:4c286db1b05d497ea6a619416308f8e82021-12-02T08:44:21ZMycophenolate mofetil in the treatment of lupus nephritis1177-54751177-5491https://doaj.org/article/4c286db1b05d497ea6a619416308f8e82008-06-01T00:00:00Zhttp://www.dovepress.com/mycophenolate-mofetil-in-the-treatment-of-lupus-nephritis-a1734https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Patrick FK Yong1,2, David P D&rsquo;Cruz21Department of Clinical Immunology, Kings College Hospital; 2The Lupus Research Unit, St Thomas&rsquo; Hospital, London, UKAbstract: Lupus nephritis is a complication of systemic lupus erythematosus, which has significant morbidity and mortality. The accepted standard of treatment for severe lupus nephritis is cyclophosphamide for induction of remission. This has significant adverse effects including severe infection and amenorrhea. In addition, although cyclophosphamide induces remission, long-term mortality does not seem to be altered. Mycophenolate mofetil (MMF) is an immunosuppressive agent originally used in solid organ transplantation, which has been compared with cyclophosphamide in trials for lupus nephritis. Randomized trials with MMF have been relatively small, although pooled data seem to suggest that it is at least as effective as cyclophosphamide in inducing remission. In addition, MMF has also been associated with a reduced risk of infection and amenorrhea, although this finding is not universal. MMF appears to be associated with more diarrhea compared with cyclophosphamide. MMF is likely to be a useful treatment for lupus nephritis, although available trial data are limited due to the small size of previous studies. A large trial (the Aspreva Lupus Management Study) is currently underway to attempt to establish the place of MMF in treatment of lupus nephritis.Keywords: mycophenolate mofetil, lupus nephritis, systemic lupus erythematosus Patrick FK YongDavid P D&rsquo;CruzDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 2, Pp 297-310 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Patrick FK Yong David P D&rsquo;Cruz Mycophenolate mofetil in the treatment of lupus nephritis
description	Patrick FK Yong1,2, David P D&rsquo;Cruz21Department of Clinical Immunology, Kings College Hospital; 2The Lupus Research Unit, St Thomas&rsquo; Hospital, London, UKAbstract: Lupus nephritis is a complication of systemic lupus erythematosus, which has significant morbidity and mortality. The accepted standard of treatment for severe lupus nephritis is cyclophosphamide for induction of remission. This has significant adverse effects including severe infection and amenorrhea. In addition, although cyclophosphamide induces remission, long-term mortality does not seem to be altered. Mycophenolate mofetil (MMF) is an immunosuppressive agent originally used in solid organ transplantation, which has been compared with cyclophosphamide in trials for lupus nephritis. Randomized trials with MMF have been relatively small, although pooled data seem to suggest that it is at least as effective as cyclophosphamide in inducing remission. In addition, MMF has also been associated with a reduced risk of infection and amenorrhea, although this finding is not universal. MMF appears to be associated with more diarrhea compared with cyclophosphamide. MMF is likely to be a useful treatment for lupus nephritis, although available trial data are limited due to the small size of previous studies. A large trial (the Aspreva Lupus Management Study) is currently underway to attempt to establish the place of MMF in treatment of lupus nephritis.Keywords: mycophenolate mofetil, lupus nephritis, systemic lupus erythematosus
format	article
author	Patrick FK Yong David P D&rsquo;Cruz
author_facet	Patrick FK Yong David P D&rsquo;Cruz
author_sort	Patrick FK Yong
title	Mycophenolate mofetil in the treatment of lupus nephritis
title_short	Mycophenolate mofetil in the treatment of lupus nephritis
title_full	Mycophenolate mofetil in the treatment of lupus nephritis
title_fullStr	Mycophenolate mofetil in the treatment of lupus nephritis
title_full_unstemmed	Mycophenolate mofetil in the treatment of lupus nephritis
title_sort	mycophenolate mofetil in the treatment of lupus nephritis
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/4c286db1b05d497ea6a619416308f8e8
work_keys_str_mv	AT patrickfkyong mycophenolatemofetilinthetreatmentoflupusnephritis AT davidpdamprsquocruz mycophenolatemofetilinthetreatmentoflupusnephritis
_version_	1718398415286566912

Mycophenolate mofetil in the treatment of lupus nephritis

Ejemplares similares